EIP logo

Copyright © 2007-2024 European Immunogenicity Platform

Location photo

16th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals

24th — 26th February 2025

Lisbon, Portugal

We look forward to seeing you in Lisbon for another great conference.

Registration prices

Members

Non members

Academics

Symposium & Workshop

900€

1,200€

900€

Conference only

700€

1,100€

700€

Workshop only

390€

390€

390€

  • All prices include 23% VAT.
  • The EIP Board invites you to be our guest at the social event. If you wish to attend, please ensure that you select this option when booking. Upon confirmation of attendance to the social event, please note that in case of no show a fee of 100.00€ will be charged to cover the costs incurred by EIP.

Deadline for registration

14th February 2025

Sponsoring opportunities

Our annual symposium is the perfect place for your organisation to promote your products and services to an audience of scientific experts active in the area of immunogenicity. The sponsor package includes:

  • a booth at the conference hotel
  • a free page in the brochure containing the conference agenda
  • your logo on the sponsor page of the program
  • your logo on the conference page of the EIP website
  • free entrance to the meeting for 2 delegates from your company
  • full access to the conference including the scientific presentations
  • two free invitations to the social event

Package prices:

  • for members of the European Immunogenicity Platform: 10,000 €
  • for non-members of the European Immunogenicity Platform: 14,000 €

Please email Barbara Vercruyssen if you wish to sponsor the event

After registering as a sponsor, you will receive an invoice. Upon settlement of this invoice, the sponsoring is accepted.

The next step is then to provide us with:

  • Your company details and contact person’s name, phone number and email address
  • A visual (photo/image/logo) from your organisation
  • The URL of your website
  • An optional YouTube embed URL

Deadline submission material: December 1, 2025
Deadline booth material at Altis Grand Hotel: February 1, 2025
Material needs to be shipped to:
EIP - Altis Grand Hotel, Rua Barata Salgueiro 50, 1250-096 Lisboa, Portugal
For the attention of: Claudia
Conference: EIP, 24th—26th February 2025 (contact: Barbara Vercruyssen)

 The deadline for sponsoring is 1st February 2025

Program

Download the program as a PDF
NOTE: Preliminary program published 27/11/2024, potentially subject to change.
 

Monday, February 24 th 2025

Workshop Day
09:00 Coming Together
09:15 Challenging the current paradigms for clinical immunogenicity testing – the pros and cons
Daniel Kramer, Sanofi
Arno Kromminga, BioNTech
Sebastian Spindeldreher, Integrated Biologix
Christopher Tiedje, BioAgilytix
Lydia Michaut, Novartis
10:15 coffee Coffee Break
10:45 Continue “Challenging the current paradigms for clinical immunogenicity testing the pros and cons”
12:15 cutlery 77 Lunch
13:30 Bring Your own Problems (Break out Sessions)
Daniel Kramer, Sanofi
Arno Kromminga, BioNTech
Sebastian Spindeldreher, Integrated Biologix
Sofie Pattijn, IQVIA
Noel Smith, Lonza
Sophie Tourdot, Pfizer
Tim Hickling, Roche
ydia Michaut, Novartis
15:00 coffee Coffee Break
15:30 Continue “Bring Your own Problems (Break out Sessions)”
16:30 Closing of the Workshop Day
17:00 18:30 Meeting of the EIP Working Groups
Members of EIP working groups
 

Tuesday, February 25th 2025

09:00 Welcome and Introduction by the EIP Chairman
Daniel Kramer, Sanofi
09:15 Spotlight Presentations: Topic to be confimred
Speaker to be confirmed
Session 2: Prediction of Immunogenicity
Chair: Sebastian Spindeldreher
10:15 EIP NCIRA Working Group Update
Sebastian Spindeldreher, Integrated Biologix on behalf of EIP
10:30 Analyzing and decreasing the immunogenicity potential of biotherapeutics using in silico approaches
Michael Gutknecht, Novartis - invited
11:00 coffee Coffee Break
11:30 Enhancing Large Molecule Design by Early Integration of MAPPs using Defined Allele Antigen Presenting Cells
Andreas Hollenstein, Roche
12:00 The localization of T-cell epitopes in biopharmaceuticals: from peptides to gene therapy vectors
Bernard Maillere, University Paris-Saclay
12:30 cutlery 77 Lunch Break
13:30 Internalization of therapeutic antibodies into Dendritic cells as a risk factor for immunogenicity
Michel Siegel, Roche
14:00 Aggregation of therapeutic antibodies enhances dendritic cell uptake and T-cell responses
Marc Pallardy, INSERM
14:30 Suitable peptide controls for screening generic peptide products in adaptive immunogenicity assays
Chloë Ackaert, IQVIA - invited
15:00 coffee Coffee Break
Session 3: Immunogenicity Assays
Chair: Arno Kromminga
15:30 EIP Immunogenicity Assays Working Group Update
Linlin Luo, Merck Sharp & Dome on behalf of EIP
15:45 Current industry practices for in-study cut point setting for clinical immunogenicity assays
Riejanne Bax-Seigers, Icon
16:15 Comparing Signal-to-Noise with titer results – a retrospective analysis
Karin Benstein, Sanofi
16:45 Addressing Target Interference During the Development of a Neutralizing Anti-Drug Antibody Assay for the clinical support of a bispecific therapeutic antibody
Saskia van der Lee, Genmab
Session 3: Social Event
Chair: Barbara Vercruyssen
18:00 multiple 11 Get Together
23:00 moon stars Good Night
 

Wedneday, February 26th 2024

Session 4: Immunogenicity Assays continued
Chair: Arno Kromminga
09:00 Fit-for-purpose non-clinical immunogenicity assessment to support PK data interpretation – a case study
Christopher Tiedje, BioAgilytix
09:30 Evaluating and Mitigating Pre-existing Anti-Drug Antibodies of Bi-Specific Therapeutic Proteins in Early Drug Discovery: A Roche Case Study
Janine Faigle, Roche
Short Talks (15 min)
10:00 A retrospective analysis of clinical immunogenicity data – time for singlicate change
Sandra Ribes Miravet, Sandoz Deutschland/Hexal AG - invited
10:15 Is ADA-tiered approach suitable to therapeutics with pre-existing antibodies?
Issa Jyamubandi, Intertek
10:30 coffee Coffee Break
11:00 Generation of anti-drug antibody (ADA) positive control and development of a bridging immunogenicity assay for RNA therapeutics in human serum
Oli Gnana Rajaraman, AiCuris Anti-infective Cures AG
11:15 Application of SPR technology for assessment of immunogenicity of a dual-peptide cancer vaccine
Daniel Worms, BioAgilytix
11:30 In-depth characterization and semi-quantification of ADAs using innovative hybrid LC-MS methods to support clinical development of biotherapeutics
Stephane Muccio, Sanofi
Session 5: Clinical Relevance of Immunogenicity
Chair: Lydia Michaut
11:45 Analysis of Clinical Immunogenicity Data for a Multi-Study Program
Susan Irvin, Regeneron
12:15 The effects of the immune modulator methotrexate on anti-drug antibody formation
Karin Bloem, Sanquin
12:45 cutlery 77 Lunch Break
13:45 An American Association of Pharmaceutical Scientists (AAPS) Perspective on Clinical Relevance of Immunogenicity
Mohsen Rajabi, Novartis (on behalf of AAPS)
Session 5: Immunogenicity of Novel Modalities
Chair: Noel Smith
14:15 The successes in treatment of cancer patients with immunotherapies including T-cell chimeric antigen receptor T-cells (CAR-T)
Amy Rosenberg, Epivax
14:45 Exploring alternatives to the 3-tiered immunogenicity testing paradigm for gene therapy programs
Robert Nelson, BioAgilytix
Session 6: Regulatory
Chair: Daniel Kramer
15:15 Applying Innate immune response modulating impurities testing for immunogenicity risk assessments: Statistical and regulatory considerations
Daniela Verthelyi, FDA
15:45 Topic to be confirmed
Speaker to be confirmed
16:15 Conference Summary & Outlook by the EIP Chairman
Daniel Kramer, Sanofi
16:30 Close of the conference

Hotel accommodation

Hotel photo
Altis Grand Hotel

The conference venue. Special rates have been negotiated for conference attendees. Please book via the special EIP link for these rates to be applied.

Address

Rua Castilho 11
1269-072 Lisboa
Portugal

Phone
+351 21 310 6000
Email
reservations@altishotels.com
Hotel photo
Ibis Lisboa Centro Liberdade

Just next door to the conference venue, a 2 minute walk.

Address

Rua Barata Salgueiro 53
1250-043 Lisboa
Portugal

Phone
+351 21 330 0630
Email
h3137@accor.com
Hotel photo
Avani Avenida Liberdade Lisbon

A 10 minute walk to the conference venue.

Address

Rua Júlio César Machado 7/9
1250-135 Lisboa
Portugal

Phone
+351 21 359 1000
Email
lisbon@avani-hotels.com
Hotel photo
Ibis Styles Lisboa Centro Marquês de Pombal

A 15 minute walk to the conference venue.

Address

Av. Fontes Pereira de Melo 5
1069-114 Lisboa
Portugal

Phone
+351 21 350 3900
Email
ha9r8@accor.com

Sponsors

We are very happy to have the support of our sponsors for this year’s Symposium.

BioAgilytix

BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC bioanalytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany.

For more information, please visit the BioAgilytix website

Celerion

Celerion, a leading early clinical research organization, is equipped with the expertise and resources to surpass your bioanalytical needs, offering services from method development and validation to efficient sample analysis for studies spanning late discovery, preclinical, and late-stage clinical development. With more than 40 years of experience, our laboratories in Zürich, Switzerland, and Lincoln, Nebraska, USA, leverage cutting-edge technology and scientific expertise to accelerate drug development by swiftly providing high-quality data for thorough immunogenicity assessments, pharmacokinetics, and biomarker analysis.

For more information, please visit the Celerion website

SVAR

Svar Life Science is a Swedish group of companies that invents, develops, and applies the best assay technology for drug development and clinical diagnostics with the goal of delivering new solutions tailored to customer requirements. They offer advanced technology platforms such as Functional Complement Biomarker and Screening assays and Cell-based Reporter Gene assays, as well as unique service models for Bioassays Customization, Custom Cell line Development in combination with GxP Laboratory Services, all designed to meet their customers’ specific project needs.

For more information, please visit the SVAR website

Back to top